A Phase 2 interventional study of rituximab [MabThera/Rituxan] in Idiopathic Thrombocytopenic Purpura, sponsored by Hoffmann-La Roche. Completed at 12 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-02-23.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. Rituximab · Purpura, Thrombocytopenic, Idiopathic.
Among the 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic, this one is the 6th largest by enrollment, is one of 2 that started in 2007, is one of 9 in phase 2, and was the 6th registered.
505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic are open now, in 4 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
New York Medical College · Sites in United States
Ages 1–21
Nahda University · Sites in Egypt
Ages 18–65
Ostfold Hospital Trust
Ages 18+
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 10 · Phase 4 2
First in 2000; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 58 across 378 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 60 across the 27 interventional studies. Of the 17 that completed or were terminated, 3 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 27 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 5 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
1 of the studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206823The First Affiliated Hospital of Soochow UniversityEfficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing rituximab in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single arm study will evaluate the efficacy and safety of MabThera monotherapy in patients with refractory, relapsing or chronic idiopathic thrombocytopenic purpura (ITP). Patients will receive infusions of MabThera 1000mg i.v. on days 1 and 15. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [MabThera/Rituxan]
Drug page: Rituximab
1000mg iv on days 1 and 15
Percentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR)
Percentage of participants with an overall response at Week 8 achieving a CR or PR as evaluated by platelets, new or increased Idiopathic Thrombocytopenic Purpura (ITP)-related treatments and corticosteroids given for Adverse Events (AEs). CR was defined as a platelet count of greater than (\>) 150x10\^9/ liters (L) over at least 2 consecutive measurements at least 2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy. PR was defined as platelet count of \>50x10\^9/L over at least 2 consecutive measurements at least \<2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy. Overall response rate (participants who achieved CR or confirmed PR) was evaluated using platelets, new or increased ITP related treatments, and corticosteroids given for AEs.
Time frame: Week 8
Percentage of Participants With Hematological CR, PR, or Minor Response (MR)
Percentage of participants with CR, PR, and MR at Week 8 as evaluated by platelet count where CR is greater than or equal to (≥)150x10\^9/L, PR ≥ 50x10\^9/L, MR equals (=) 30x10\^9/L over 2 consecutive measurements at least 2 weeks apart but no more than 60 days apart with no increase in concomitant therapy or initiation of new ITP therapy.
Time frame: Week 8
Percentage of Participants Who Achieved CR
CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
Time frame: Week 52
Time to CR
Time to CR was defined as the time from the first infusion to the first date on which CR was achieved. CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy. Participants without an event were censored at the date of last assessment.
Time frame: Baseline to Week 52
Percentage of Participants Who Achieved PR
PR was defined as platelet counts \>50x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.
Time frame: Week 52
Time to PR
Time to response was defined as the time from the first infusion to the first date on which PR was achieved. PR was defined as platelet counts \> 50x10\^9/L over ≥ 2 consecutive measurements ≥ 2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.
Time frame: Baseline to Week 52
Percentage of Participants Who Achieved MR
MR was defined as participants registered with chronic ITP with a platelet count of \>30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50 to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
Time frame: Week 52
Time to MR
Time to response was defined as the time from the first infusion to the first date on which MR was achieved. MR was defined as participants registered with chronic ITP with a platelet count of \>30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50 percent (%) to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
Time frame: Baseline to Week 52
Percentage of Participants With Continued CR From Week 8 to Week 52
The number of participants with a durable CR assessed in CR responders whose responses were sustained from Week 8 through to the end of the study or withdrawal, irrespective of change of treatment. CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥ 2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
Time frame: Week 8 to Week 52
Duration of CR in Participants With Continued CR From Week 8 Until Week 52
Duration of response was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of CR, irrespective of change of treatment. CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
Time frame: Week 8 to Week 52
Duration of PR in Participants With Continued PR From Week 8 Until Week 52
Duration of PR was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of PR, irrespective of change of treatment. PR was defined as platelet counts \>50x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.
Time frame: Week 8 to Week 52
Duration of MR in Participants With Continued MR From Week 8 Until Week 52
Duration of response was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of MR, irrespective of change of treatment. MR was defined as participants registered with ITP in relapse with a platelet count of \> 30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy. Participants registered with chronic ITP with a platelet count of \>30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50% to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
Time frame: Week 8 to Week 52
Time to Inititiation of New ITP Therapy - Percentage of Participants With an Event
Percentage of participants with an event of initiation of new ITP therapy and/or increase in dose of existing ITP therapy, including date on which decision made in relation to splenectomy, from time of first treatment to Week 52.
Time frame: Week 52
Time to Initiation of New ITP Therapy
Median time in days to initiation of new ITP therapy and/or increase in dose of existing ITP therapy, including date on which decision made in relation to splenectomy, from time of first treatment to Week 52.
Time frame: Baseline to Week 52
Percentage of Therapeutic Responders
Percentage of participants with a therapeutic response, defined as achieving CR, PR, or MR assessed at Week 26 and Week 52 or hematological response, defined as achieving CR, PR, or MR at Week 8. CR was defined as no platelet response or no reduction in the dose intensity of concomitant ITP therapy compared with that at screening. PR response was defined as at least a minor platelet response that enabled a 50% to 99% reduction in the dose intensity of concomitant ITP therapy compared with that at screening. MR was defined as at least a minor platelet response that enabled a 1% to 49% reduction in the dose intensity of concomitant ITP therapy compared with that at screening.
Time frame: Week 26 and Week 52
Percentage of Participants With a Therapeutic Response
Number of therapeutic responder participants by CR, PR, MR, or no response (NR) measured at Week 26 and Week 52. CR was defined as no platelet response or no reduction in the dose intensity of concomitant ITP therapy compared with that at screening. PR was defined as at least minor platelet response that enabled a 50% to 99% reduction in the dose intensity of concomitant ITP therapy compared with that at screening. MR was defined as at least minor platelet response that enabled a 1% to 49% reduction in the dose intensity of concomitant ITP therapy compared with that at screening.
Time frame: Week 26 and Week 52
Cluster of Differentiation 19 (CD19) B Cell Count
Value of mean CD19+ B cell count at baseline. The standard reference range for CD19 is 0.05 to 0.35 x10\^9/L.
Time frame: Baseline, Weeks 1, 3, and 8, Follow-up Months 4, 6, 8, 10, and 12, and Last Day
Change From Baseline in CD19 B Cell Count
Actual values of CD19+ mean B cell count assessed at Weeks 3 and 8, and Months 4, 6, 8, 10 and 12, and last day. The standard reference range for CD19 is 0.05 to 0.35 x10\^9/L.
Time frame: Weeks 3, 8 and Months 4, 6, 8, 10 and 12, and last day
| Milestone | Rituximab |
|---|---|
| Started | 122 |
| Completed | 90 |
| Not completed | 32 |
| Withdrew: Protocol violation | 5 |
| Withdrew: Adverse event | 4 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Lack of efficacy | 8 |
| Withdrew: Death | 1 |
| Withdrew: Reason not specified | 1 |
| Withdrew: Lost to follow-up | 7 |
Percentage of participants with an overall response at Week 8 achieving a CR or PR as evaluated by platelets, new or increased Idiopathic Thrombocytopenic Purpura (ITP)-related treatments and corticosteroids given for Adverse Events (AEs). CR was defined as a platelet count of greater than (\>) 150x10\^9/ liters (L) over at least 2 consecutive measurements at least 2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy. PR was defined as platelet count of \>50x10\^9/L over at least 2 consecutive measurements at least \<2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy. Overall response rate (participants who achieved CR or confirmed PR) was evaluated using platelets, new or increased ITP related treatments, and corticosteroids given for AEs.
| percentage of participants | Rituximab 1000 mg |
|---|---|
| Percentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR) | 43.5 (34.0 to 53.4) |
Percentage of participants with CR, PR, and MR at Week 8 as evaluated by platelet count where CR is greater than or equal to (≥)150x10\^9/L, PR ≥ 50x10\^9/L, MR equals (=) 30x10\^9/L over 2 consecutive measurements at least 2 weeks apart but no more than 60 days apart with no increase in concomitant therapy or initiation of new ITP therapy.
| percentage of participants | Rituximab 1000 mg |
|---|---|
| CR | 9.3 (4.5 to 16.4) |
| PR | 34.3 (25.4 to 44.0) |
| MR | 17.6 (10.9 to 26.1) |
CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
| percentage of participants | Rituximab 1000 mg |
|---|---|
| Percentage of Participants Who Achieved CR | 27.8 |
Time to CR was defined as the time from the first infusion to the first date on which CR was achieved. CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy. Participants without an event were censored at the date of last assessment.
| days | Rituximab 1000 mg |
|---|---|
| Time to CR | NA (305.0 to NA) |
PR was defined as platelet counts \>50x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.
| percentage of participants | Rituximab 1000 mg |
|---|---|
| Percentage of Participants Who Achieved PR | 56.5 |
Time to response was defined as the time from the first infusion to the first date on which PR was achieved. PR was defined as platelet counts \> 50x10\^9/L over ≥ 2 consecutive measurements ≥ 2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.
| days | Rituximab 1000 mg |
|---|---|
| Time to PR | 53.0 (36.0 to 152.0) |
MR was defined as participants registered with chronic ITP with a platelet count of \>30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50 to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
| percentage of participants | Rituximab 1000 mg |
|---|---|
| Percentage of Participants Who Achieved MR | 71.3 |
Time to response was defined as the time from the first infusion to the first date on which MR was achieved. MR was defined as participants registered with chronic ITP with a platelet count of \>30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50 percent (%) to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
| days | Rituximab 1000 mg |
|---|---|
| Time to MR | 22.0 (8.0 to 30.0) |
The number of participants with a durable CR assessed in CR responders whose responses were sustained from Week 8 through to the end of the study or withdrawal, irrespective of change of treatment. CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥ 2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
| percentage of participants | Rituximab 1000 mg |
|---|---|
| Percentage of Participants With Continued CR From Week 8 to Week 52 | 10 |
Duration of response was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of CR, irrespective of change of treatment. CR was defined as platelet counts \>150x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
| days | Rituximab 1000 mg |
|---|---|
| Duration of CR in Participants With Continued CR From Week 8 Until Week 52 | NA (NA to NA) |
Duration of PR was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of PR, irrespective of change of treatment. PR was defined as platelet counts \>50x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy.
| days | Rituximab 1000 mg |
|---|---|
| Duration of PR in Participants With Continued PR From Week 8 Until Week 52 | 247.0 (219.0 to NA) |
Duration of response was assessed in all responders who reached Week 8 and was defined as the time from Week 8 to the end of MR, irrespective of change of treatment. MR was defined as participants registered with ITP in relapse with a platelet count of \> 30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with no increase in concomitant ITP therapy or initiation of new ITP therapy. Participants registered with chronic ITP with a platelet count of \>30x10\^9/L over ≥2 consecutive measurements ≥2 weeks apart, but no more than 60 days apart, with a 50% to 100% reduction in the dose intensity of concomitant ITP therapy compared with that at screening, and with no increase in concomitant ITP therapy or initiation of new ITP therapy.
| days | Rituximab 1000 mg |
|---|---|
| Duration of MR in Participants With Continued MR From Week 8 Until Week 52 | 256.0 (168.0 to NA) |
Percentage of participants with an event of initiation of new ITP therapy and/or increase in dose of existing ITP therapy, including date on which decision made in relation to splenectomy, from time of first treatment to Week 52.
| percentage of participants | Rituximab 1000 mg |
|---|---|
| Time to Inititiation of New ITP Therapy - Percentage of Participants With an Event | 50.0 |
Median time in days to initiation of new ITP therapy and/or increase in dose of existing ITP therapy, including date on which decision made in relation to splenectomy, from time of first treatment to Week 52.
| days | Rituximab 1000 mg |
|---|---|
| Time to Initiation of New ITP Therapy | 314.0 (215.0 to NA) |
Percentage of participants with a therapeutic response, defined as achieving CR, PR, or MR assessed at Week 26 and Week 52 or hematological response, defined as achieving CR, PR, or MR at Week 8. CR was defined as no platelet response or no reduction in the dose intensity of concomitant ITP therapy compared with that at screening. PR response was defined as at least a minor platelet response that enabled a 50% to 99% reduction in the dose intensity of concomitant ITP therapy compared with that at screening. MR was defined as at least a minor platelet response that enabled a 1% to 49% reduction in the dose intensity of concomitant ITP therapy compared with that at screening.
| percentage of participants | Rituximab 1000 mg |
|---|---|
| Week 26 | 43.5 |
| Week 52 | 35.2 |
Number of therapeutic responder participants by CR, PR, MR, or no response (NR) measured at Week 26 and Week 52. CR was defined as no platelet response or no reduction in the dose intensity of concomitant ITP therapy compared with that at screening. PR was defined as at least minor platelet response that enabled a 50% to 99% reduction in the dose intensity of concomitant ITP therapy compared with that at screening. MR was defined as at least minor platelet response that enabled a 1% to 49% reduction in the dose intensity of concomitant ITP therapy compared with that at screening.
| percentage participants | Rituximab 1000 mg |
|---|---|
| Week 26: CR | 38.0 (28.8 to 47.8) |
| Week 26: PR | 5.6 (2.1 to 11.7) |
| Week 26: MR | 0.0 (0.0 to 3.4) |
| Week 26: NR | 56.5 (46.6 to 66.0) |
| Week 52: CR | 35.2 (26.2 to 45.0) |
| Week 52: PR | 0.0 (0.0 to 3.4) |
| Week 52: MR | 0.0 (0.0 to 3.4) |
| Week 52: NR | 64.8 (55.0 to 73.8) |
Value of mean CD19+ B cell count at baseline. The standard reference range for CD19 is 0.05 to 0.35 x10\^9/L.
| 10^9 cells/L | Rituximab 1000 mg |
|---|---|
| Baseline (n=84) | 0.27 ± 0.374 |
| Week 1 (n=3) | 0.30 ± 0.251 |
| Week 3 (n=96) | 0.01 ± 0.052 |
| Week 8 (n=89) | 0.01 ± 0.033 |
| Follow-up Month 4 (n=57) | 0.01 ± 0.029 |
| Follow-up Month 6 (n=79) | 0.03 ± 0.041 |
| Follow-up Month 8 (n=57) | 0.07 ± 0.085 |
| Follow-up Month 10 (n=48) | 0.15 ± 0.315 |
| Follow-up Month 12 (n=70) | 0.18 ± 0.289 |
| Last Day (n=101) | 0.13 ± 0.252 |
Actual values of CD19+ mean B cell count assessed at Weeks 3 and 8, and Months 4, 6, 8, 10 and 12, and last day. The standard reference range for CD19 is 0.05 to 0.35 x10\^9/L.
| 10^9 cells/L | Rituximab 1000 mg |
|---|---|
| Week 3 (n=81) | -0.23 ± 0.290 |
| Week 8 (n=75) | -0.27 ± 0.393 |
| Follow-up Month 4 (n=47) | -0.21 ± 0.217 |
| Follow-up Month 6 (n=63) | -0.23 ± 0.367 |
| Follow-up Month 8 (n=44) | -0.22 ± 0.412 |
| Follow-up Month 10 (n=39) | -0.08 ± 0.207 |
| Follow-up Month 12 (n=55) | -0.06 ± 0.409 |
| Last Day (n=84) | -0.13 ± 0.389 |
Collected over Up to Week 52. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab 1000 mg | — | 12/122 (9.8%) | 62/122 (50.8%) |
| Event | Rituximab 1000 mg |
|---|---|
| AsbestosisInjury, poisoning and procedural complications | 1/122 |
| Spinal Compression FractureInjury, poisoning and procedural complications | 1/122 |
| Spinal FractureInjury, poisoning and procedural complications | 1/122 |
| Subdural HaematomaInjury, poisoning and procedural complications | 1/122 |
| Subdural HaemorrhageInjury, poisoning and procedural complications | 1/122 |
| Back PainMusculoskeletal and connective tissue disorders | 1/122 |
| OsteoporosisMusculoskeletal and connective tissue disorders | 1/122 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 1/122 |
| Lower Respiratory Tract InfectionInfections and infestations | 1/122 |
| Streptococcal BacteraemiaInfections and infestations | 1/122 |
| Event | Rituximab 1000 mg |
|---|---|
| ContusionInjury, poisoning and procedural complications | 9/122 |
| FatigueGeneral disorders | 7/122 |
| HeadacheNervous system disorders | 7/122 |
| NasopharyngitisInfections and infestations | 5/122 |
| DiarrhoeaGastrointestinal disorders | 5/122 |
| PetechiaeSkin and subcutaneous tissue disorders | 5/122 |
| RashSkin and subcutaneous tissue disorders | 5/122 |
| Upper respiratory tract infectionInfections and infestations | 4/122 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 4/122 |
| Gingival bleedingGastrointestinal disorders | 3/122 |
Safety population: all participants who received at least one dose of study medication and for whom follow-up safety information was available.
| Age, Continuous(years) | Rituximab |
|---|---|
| Mean | 49.5 ± 18.59 |
| Sex: Female, Male(Participants) | Rituximab |
|---|---|
| Female | 70 |
| Male | 52 |
The record gives a start of May 2007, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab
Purpura, Thrombocytopenic, Idiopathic →